Blog-Featured

VERO Biotech’s GENOSYL® Delivery System recognized as a “Technological Breakthrough” at Premier, Inc.’s Annual Supplier Innovation Celebration

Vero will be honored as an "Innovative Supplier" at Premier's…
Blog-Featured

VERO Biotech’s Second Generation GENOSYL® Delivery System (DS) Receives FDA Approval in Anesthesia in the Surgical Suite

Second Generation GENOSYL® DS is the first and only Inhaled…
Blog-Featured

VERO Biotech Raises $30 Million to Accelerate Commercialization of Its Innovative Tankless Inhaled Nitric Oxide Delivery System

Financing led by Petrichor strengthens VERO Biotech's position…
Blog-Featured

Georgia Bio Awards VERO Biotech the 2022 Golden Helix Innovation Award and Deal of the Year Award

Atlanta-based innovative company is recognized for its flagship…
Blog-Featured

VERO Biotech Receives Funding from MVM Partners to Accelerate Growth

Investment from MVM Partners to support the growth of…
Blog-Featured

VERO Biotech Secures $50 Million Funding from Runway Growth Capital

A senior secured term loan will support the further development…
Blog-Featured

FDA Approves Interhospital Patient Transport Use of VERO Biotech’s GENOSYL® Delivery System, Resulting in the Broadest Label in the Inhaled Nitric Oxide Space

The GENOSYL® DS facilitates patient treatment in interhospital…
Blog-Featured

Home Use of GENOSYL® Delivery System (DS) to Administer GENOSYL® (nitric oxide) gas for Inhalation for the Treatment of Pulmonary Hypertension Complicated by COVID-19 Infection Published in American Journal of Respiratory and Critical Care Medicine

Clinicians report on first at-home treatment of COVID-19 patient…